查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018541

免疫組織化學市場：2026-2032年全球市場預測（依產品類型、技術、檢體類型、應用、適應症和最終用戶分類）

Immunohistochemistry Market by Product Category, Technology, Specimen Type, Application, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，免疫組織化學市場價值將達到 33.3 億美元，到 2026 年將成長至 35.3 億美元，到 2032 年將達到 50.7 億美元，複合年成長率為 6.16%。

主要市場統計數據
基準年 2025 33.3億美元
預計年份：2026年 35.3億美元
預測年份 2032 50.7億美元
複合年成長率 (%) 6.16%

免疫組織化學進行了簡要概述，展現了近期技術進步、臨床期望以及檢查室。

免疫組織化學 (IHC) 處於病理學、診斷學和治療方法研發的交匯點，提供至關重要的組織層面信息，推動腫瘤學、神經科學和免疫學領域的研究。抗體工程、檢測化學和成像技術的進步，拓展了這項技術的效用，使其超越了傳統組織病理學的範疇，並確立了 IHC 作為生物標記檢驗和伴隨診斷基石的地位。自動化染色平台的成熟和數位影像分析的整合也顯著提升了處理能力和可重複性，使檢查室能夠在提高數據品質和可追溯性的同時，擴展工作流程。

自動化、數位病理學、試劑工程和監管影響等融合趨勢正在全面重新定義免疫組織化學的工作流程和能力。

近年來，在自動化和數位化技術的進步、試劑創新以及臨床重點轉變的推動下，免疫組織化學領域發生了變革性的變化。自動化技術已從基本的切片染色機發展到集染色、基於條碼的檢體追蹤和遠端監控於一體的整合系統，從而減少了人為操作的差異，並實現了可預測的處理能力。同時，數位病理學和全切片成像技術也日趨成熟，能夠支援定量影像分析。這使得病理學家能夠獲得可重複的指標，並將結構化資料整合到臨床工作流程和研究流程中。

2025 年收費系統​​的變化將如何影響檢查室籌資策略、設備生命週期決策和供應鏈韌性？

2025年的關稅政策趨勢為免疫組織化學領域的檢查室和供應鏈管理人員帶來了具體的成本和採購的考量。關稅結構和進口限制的變化正在影響關鍵投入品的到貨成本，尤其是那些依賴全球製造網路的特殊試劑、檢測基材和昂貴設備。為此，採購團隊正在重新評估其籌資策略，協商長期合約以規避價格波動風險，並選擇生產地點多元化的供應商以降低單一國家關稅變化帶來的風險。

基於細分的實用見解揭示了試劑形式、儀器架構和服務交付如何相互交織並影響檢測性能和檢查室工作流程。

透過對試劑/試劑盒、儀器和軟體/服務進行細分，我們獲得了深入的洞察，揭示了整個免疫組織化學生態系統中存在的差異化機會和營運挑戰。抗體仍是試劑和試劑盒的核心，單株抗體、多克隆抗體和重組抗體在特異性、可重複性和檢驗難度方面各有優劣。同時，各類緩衝液和封片劑，例如抗原回收緩衝液、封片劑和洗滌緩衝液，有助於提升檢測效能和檢體完整性。檢測試劑已發展出多種類型，包括酶標記系統、螢光染料標記系統和聚合物基檢測系統，從而實現了多重檢測並提高了訊號穩定性。基材和固色劑，例如AEC和DAB，繼續為標準工作流程提供支持，並擁有成熟的判讀框架。

美洲、歐洲、中東和非洲以及亞太地區的區域部署模式和營運重點，決定了採購和部署策略。

區域趨勢影響著免疫組織化學領域的應用模式、監管重點和投資策略。在美洲，大規模臨床網路和研究機構推動對自動化和整合化數位病理解決方案的需求，尤其對支持腫瘤學和免疫療法研究的多重檢測方法有著強勁的需求。採購週期通常體現了集中採購的優勢，重點檢驗且擴充性的平台，以支援高通量診斷。同時，區域監管要求強調嚴格的檢測方法檢驗和檢查室認證。

以互通性、試劑創新和服務商品搭售為核心的供應商策略，正在重新定義免疫組織化學領域的競爭優勢和營運價值。

免疫組織化學領域的公司競爭格局主要受平台互通性、試劑產品組合的廣度以及支援服務的影響。市場領導者透過完善的試劑庫、檢驗的封閉式和開放式染色系統方案以及與數位病理和全切片成像供應商的夥伴關係來提升自身競爭力。投資於重組抗體技術和多重檢測化學反應技術的公司往往能夠吸引專注於新型生物標記發現和腫瘤免疫分析的研究中心。

產業領導者可以採取切實可行的策略步驟，以增強檢查室環境的互通性、試劑創新、卓越服務和供應鏈韌性。

產業領導企業應採取夥伴關係切實可行的措施，使其產品開發、商業策略和檢查室與免疫組織化學領域的最新趨勢保持一致。首先，應優先考慮試劑、儀器和軟體之間的互通性，以減輕檢驗負擔並加速應用。確保試劑和檢測系統在封閉式和開放式染色平台上的無縫檢驗，可擴大適用範圍並簡化採購決策。其次，應投資重組抗體開發和多重檢測化學技術，以滿足腫瘤學和免疫學研究中複雜的表現型分析需求，從而吸引尋求先進診斷技術的轉化研究人員和臨床檢查室。

採用嚴謹的混合方法研究途徑，結合相關人員訪談、技術文件審查和情境分析，得出以檢查室觀點的實用見解。

本執行摘要的調查方法融合了多種途徑，以確保提供平衡可靠的見解。對實驗室負責人、病理學家、採購經理和研發主管的訪談，直接觀點了營運重點和挑戰。二級資訊來源包括關於抗體技術、試劑化學和數位病理學創新的同行評審文獻，以及供應商的技術文件和監管指南，這些資料闡述了檢驗和合規性方面的考慮。

整體結論強調可重複性、互通性和以服務為導向的策略，以將免疫組織化學的進展轉化為臨床影響。

總之，免疫組織化學正從一系列獨立技術發展成為一個整合的組織分析生態系統，該系統結合了先進的試劑、自動化設備和數位分析技術。檢查室和供應商若能優先考慮可重複性、互通性和售後服務，將為該技術的持續應用和臨床應用創造條件。供應商和檢查室負責人都需要採取協調一致的策略性應對措施，以應對臨床對精準診斷的需求、冗餘和成像技術的進步，以及供應鏈和法規環境的現實等多重壓力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依產品類型的免疫組織化學市場

  • 抗體
    • 一抗
      • 單株抗體
      • 老鼠
      • 兔子
      • 多克隆抗體
      • 重組單株抗體
      • 重組片段
      • scFv
      • Fab
    • 二抗
      • 酵素標記
      • 生物素化
      • 螢光染料標記
      • 未標記
  • 檢測系統
    • 聚合物
    • 親和素-生物素
    • 酪胺擴增
  • 固色劑和對比色劑
    • DAB
    • AEC
    • 快紅
    • 蘇木精
  • 輔助試劑
    • 恢復緩衝液
    • 封閉試劑
    • 洗滌緩衝液
  • 套件和麵板
    • 單支記號筆套裝
    • 連接複用面板

第9章 免疫組織化學市場：依技術分類

  • 免疫組化染色顯示
    • HRP/DAB
    • AP/紅色
    • 雙酵素法
  • 螢光
    • 單工IF
    • 連接複用中頻
      • 2-3 Plex
      • 4-7 Plex
      • 8+plex
  • 訊號放大
    • 酪胺訊號放大
    • 基於生物素的擴增
  • 金屬標記免疫組織化學
    • 相容質譜流式細胞儀
    • 相容 MIBI

第10章：依檢體類型分類的免疫組織化學市場

  • FFPE組織
    • 切除
    • 切片檢查
  • 冷凍組織
    • 冰凍切片
  • 細胞學檢體
    • 塗抹
    • 液體標本
  • 組織微陣列

第11章 免疫組織化學市場：依應用領域分類

  • 臨床診斷
    • 腫瘤學
      • 固態腫瘤
      • 血液病理學
    • 感染疾病
    • 移植免疫病理學
    • 神經病理學
    • 心血管病理
    • 伴隨診斷
  • 研究與藥物發現
    • 基礎研究
    • 轉化研究
    • 目標檢驗
    • 生物標記發現
    • 毒性病理學
  • 獸醫病理學
  • 法醫學病理學
  • 教育和培訓

第12章：免疫組織化學市場：依適應症分類

  • 腫瘤學
    • 乳癌
    • 肺癌
    • 結腸癌
    • 攝護腺癌
    • 惡性黑色素瘤
    • 淋巴瘤
    • 腦腫瘤
  • 感染疾病
    • 病毒性的
    • 細菌
    • 真菌
  • 自體免疫/發炎性疾病
    • 系統性自體免疫疾病
    • 消化器官系統發炎疾病
  • 神經系統疾病
    • 神經退化性疾病
  • 腎臟和肝臟
    • 腎臟疾病
    • 肝病

第13章 免疫組織化學市場：依最終用戶分類

  • 醫院檢查室
    • 當地醫院
    • 大學醫院
  • 檢驗承包組織
  • 學術和研究機構
  • 製藥和生物技術
    • 院內檢查室
    • 外部承包商
  • 合約研究機構
  • 獸醫病理檢查室

第14章 免疫組織化學市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：免疫組織化學市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 免疫組織化學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國免疫組織化學市場

第18章 中國免疫組織化學市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Abcam plc
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biogenex Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • Danaher Corporation
  • Enzo Life Sciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • Histo-Line Laboratories
  • Leica Biosystems Nussloch GmbH
  • Merck KGaA
  • Miltenyi Biotec BV & Co. KG
  • Novus Biologicals, LLC
  • OriGene Technologies, Inc.
  • PerkinElmer, Inc.
  • R&D Systems, Inc.
  • Santa Cruz Biotechnology, Inc.
  • Sigma-Aldrich Co. LLC
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Vector Laboratories, Inc.
  • Wako Pure Chemical Industries, Ltd.
  • ZenBio, Inc.
Product Code: MRR-A339DAEFADE0

The Immunohistochemistry Market was valued at USD 3.33 billion in 2025 and is projected to grow to USD 3.53 billion in 2026, with a CAGR of 6.16%, reaching USD 5.07 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.33 billion
Estimated Year [2026] USD 3.53 billion
Forecast Year [2032] USD 5.07 billion
CAGR (%) 6.16%

A concise orientation to immunohistochemistry that frames recent technical advances, clinical expectations, and operational pressures reshaping laboratory decisions

Immunohistochemistry (IHC) stands at the confluence of pathology, diagnostics, and therapeutic development, offering vital tissue-level insights that guide oncology, neuroscience, and immunology research. Advances in antibody engineering, detection chemistries, and imaging modalities have expanded the technique's utility beyond traditional histopathology, positioning IHC as a cornerstone of biomarker validation and companion diagnostics. The maturation of automated staining platforms and the integration of digital image analysis have also transformed throughput and reproducibility, enabling laboratories to scale workflows while enhancing data quality and traceability.

Clinicians and laboratory directors now expect faster turnaround, higher multiplexing capability, and tighter quality controls to support precision medicine initiatives. Concurrently, academic and industry researchers demand flexible reagents and robust detection systems that accommodate emerging targets and complex tissue types. These shifting expectations shape procurement decisions, influence instrument upgrade cycles, and direct investment in training and maintenance services. As stakeholders adapt to evolving clinical standards and regulatory scrutiny, IHC suppliers and service providers must balance innovation with validated performance and interoperability.

This executive summary synthesizes the critical developments affecting reagent portfolios, instrument architectures, and software ecosystems. It highlights practical implications for purchasing teams and laboratory managers, and it frames strategic considerations for executives seeking to align product roadmaps with clinical and research priorities. By focusing on reproducibility, scalability, and integration across the diagnostic value chain, organizations can navigate immediate operational pressures while building capacity for future diagnostic paradigms.

Converging trends in automation, digital pathology, reagent engineering, and regulatory influence that collectively redefine immunohistochemistry workflows and capabilities

Recent years have seen transformative shifts in the immunohistochemistry landscape driven by automation, digital convergence, reagent innovation, and shifting clinical priorities. Automation has progressed from basic slide stainers to integrated systems that combine staining, barcode-driven sample tracking, and remote monitoring, which collectively reduce manual variability and enable predictable throughput. Meanwhile, digital pathology and whole slide imaging have matured to support quantitative image analysis, enabling pathologists to derive reproducible metrics and feed structured data into clinical workflows and research pipelines.

On the reagents front, antibody engineering has accelerated the adoption of recombinant antibodies and renewable monoclonal formats, improving lot-to-lot consistency and reducing validation burden. Detection chemistries have evolved to include polymer-based systems and multiplex-capable fluorophores that support simultaneous visualization of multiple biomarkers within a single tissue section. These advances enable more nuanced phenotyping of tumor microenvironments and immune infiltrates, thereby improving the granularity of diagnostic and translational studies.

Concurrently, there is a pronounced shift toward integrated software and services that augment laboratory capabilities. Data analysis platforms now incorporate machine learning tools for pattern recognition and cell phenotyping, while consulting and training services help sites validate new assays and comply with regulatory expectations. Regulatory frameworks and payer considerations have also begun to influence reagent validation pathways and instrument qualification processes, prompting suppliers to prioritize robust documentation and interoperability. Taken together, these trends signal a move from isolated tools toward cohesive ecosystems that support end-to-end tissue analytics and translational research objectives.

How evolving tariff dynamics in 2025 are reshaping procurement strategies, instrument lifecycle decisions, and supply chain resilience for laboratories

Tariff policy developments in 2025 have introduced tangible cost and procurement considerations for laboratories and supply chain managers involved in immunohistochemistry. Changes in duty structures and import controls have affected the landed cost of key inputs, particularly for specialized reagents, detection substrates, and high-value instruments that rely on global manufacturing networks. Procurement teams have responded by reevaluating sourcing strategies, negotiating longer-term contracts to hedge against price volatility, and seeking suppliers with diversified production footprints to reduce exposure to single-country tariff shifts.

Instruments, including automated stainers and slide scanners, have been particularly sensitive to cross-border cost adjustments because they often incorporate components sourced internationally and arrive with substantial freight and compliance overhead. Changes in tariffs have influenced replacement cycles and upgrade timing, as laboratories balance capital investments against operating budget constraints. Smaller clinical laboratories and research centers have felt pressure to maintain service levels while absorbing higher consumable costs, prompting many to explore centralized testing models or consortium purchasing to regain purchasing leverage.

At the same time, the tariff environment has spurred domestic manufacturers and distributors to emphasize local inventory buffers and faster lead-times. This emphasis supports continuity of care and reduces the operational risk associated with supply interruptions. For decision-makers, the practical implication is clear: procurement strategies must incorporate scenario planning that accounts for trade policy dynamics, supplier resilience, and the total cost of ownership rather than line-item cost alone. By doing so, lab directors can protect assay integrity, maintain turnaround commitments, and preserve research continuity amid an uncertain trade landscape.

Practical segmentation-driven insights revealing how reagent formats, instrument architectures, and service offerings intersect to influence assay performance and laboratory workflows

Insights derived from segmentation across reagents and kits, instruments, and software and services reveal differentiated opportunities and operational challenges across the immunohistochemistry ecosystem. Within reagents and kits, antibodies remain central, with monoclonal, polyclonal, and recombinant formats each offering trade-offs in specificity, reproducibility, and validation overhead; meanwhile, buffers and mounting media categories such as antigen retrieval buffers, mounting media, and washing buffers underpin assay performance and sample integrity. Detection reagents have diversified into enzyme-labeled systems, fluorophore-labeled systems, and polymer-based detection systems that enable multiplexing and enhanced signal stability, while substrates and chromogens like AEC and DAB continue to support standard workflows with established interpretive frameworks.

Turning to instruments, automated stainers have bifurcated into closed system stainers that offer validated, turnkey protocols and open system stainers that provide flexibility for bespoke assays; imaging systems now encompass digital pathology software and whole slide imaging platforms that drive downstream analytics; microscopes retain a central role for detailed interpretation and troubleshooting, with bright field, confocal, and fluorescence modalities supporting a range of clinical and research needs; and slide scanners facilitate high-resolution digitization that underpins remote review and computational pathology workflows. The interplay between instrument architecture and reagent compatibility has become a key consideration for laboratories seeking to maximize throughput while preserving assay fidelity.

Software and services complete the ecosystem by addressing the operational and analytical demands of modern IHC practice. Consulting services support assay development and validation processes, data analysis software enables quantitative interpretation and supports regulatory documentation, maintenance services ensure instrument uptime and calibration, and training services build staff capability for new platforms and assays. Together, these segments point to a market where integrated solutions that reduce validation burden and ease workflow transitions command a premium, while modular approaches that enable selective adoption of digital and multiplexing capabilities support customization for diverse laboratory profiles.

Regional adoption patterns and operational priorities across the Americas, Europe Middle East and Africa, and Asia-Pacific that shape procurement and implementation strategies

Regional dynamics shape adoption patterns, regulatory priorities, and investment approaches across the immunohistochemistry landscape. In the Americas, large clinical networks and research institutions drive demand for automation and integrated digital pathology solutions, and there is strong appetite for multiplex assays that support oncology and immunotherapy research. Procurement cycles often reflect centralized purchasing power and a focus on validated, scalable platforms that support high-throughput diagnostics, while regional regulatory expectations emphasize rigorous assay validation and laboratory accreditation.

In Europe, the Middle East, and Africa, heterogeneous healthcare systems and varying regulatory environments create a patchwork of adoption rates and priorities. Major European markets show steady uptake of advanced imaging and recombinant reagent formats, supported by strong translational research ecosystems and collaborative networks. In contrast, some markets within the broader region emphasize cost-effectiveness and robust training and maintenance services to extend the life of existing instrumentation. Regulatory harmonization efforts in Europe complement investments in digital pathology infrastructure, enabling cross-border research collaborations and data sharing initiatives.

The Asia-Pacific region continues to present a dynamic mix of rapid technology adoption and capacity building. Large academic centers and commercial labs in several markets are rapidly implementing automation and whole slide imaging to support burgeoning oncology research programs. At the same time, diverse market maturity levels mean that smaller clinics and regional laboratories often prioritize cost-efficient reagent systems and practical training services. Across the region, investments in local manufacturing and distribution channels are increasing to mitigate supply chain risks and meet growing clinical demand.

How supplier strategies centered on interoperability, reagent innovation, and service bundling are redefining competitive advantage and operational value in immunohistochemistry

Competitive dynamics among companies in the immunohistochemistry space emphasize platform interoperability, reagent portfolio breadth, and support services. Market leaders differentiate through comprehensive reagent libraries, validated protocols for closed and open stainer systems, and partnerships that expand compatibility with digital pathology and whole slide imaging providers. Firms that invest in recombinant antibody technologies and multiplex-capable detection chemistries tend to attract research centers focused on novel biomarker discovery and immune-oncology profiling.

Service-oriented providers gain traction by bundling maintenance, training, and consulting offerings that reduce the total cost of assay adoption for clinical laboratories and research institutions. Conversely, agile niche players that specialize in specialized substrates, chromogens, or tailored detection reagents find opportunities in labs requiring bespoke solutions or rapid validation cycles. Strategic collaborations between instrument manufacturers and software vendors continue to shape the competitive landscape by offering integrated workflows that reduce validation time and support regulatory documentation.

For purchasing and R&D leaders, the practical takeaway is to evaluate suppliers not only on individual product performance but also on their capacity to deliver end-to-end solutions, timely technical support, and collaborative validation assistance. The vendors that provide clear interoperability roadmaps, responsive field service footprints, and repeatable assay protocols will likely offer the greatest operational value as laboratories modernize workflows and embrace digital analytics.

Actionable strategic steps industry leaders can take to strengthen interoperability, reagent innovation, service excellence, and supply chain resilience in laboratory environments

Industry leaders should pursue a set of actionable steps to align product development, commercial strategy, and laboratory partnerships with current trends in immunohistochemistry. First, prioritize interoperability across reagents, instruments, and software to reduce validation burden and accelerate adoption. Ensuring that reagents and detection systems validate seamlessly on both closed and open stainer platforms will expand addressable use cases and ease procurement decisions. Second, invest in recombinant antibody development and multiplex-capable detection chemistries to support the complex phenotyping needs of oncology and immunology research, thereby appealing to translational researchers and clinical laboratories seeking advanced diagnostics.

Third, build robust service offerings including maintenance contracts, training programs, and consulting support that de-risk adoption for laboratories with limited internal validation resources. Fourth, develop supply chain resilience through diversified manufacturing footprints and strategic inventory management to mitigate exposure to tariff shifts and geopolitical disruptions. Fifth, collaborate with digital pathology and data analysis providers to create validated end-to-end workflows that combine staining, imaging, and quantitative analysis, and ensure compliance with regional regulatory expectations. Finally, engage with clinical and research customers through pilot studies and co-development projects to refine product-market fit and demonstrate real-world utility, using iterative feedback to inform roadmaps and support materials.

Rigorous mixed-methods research approach combining stakeholder interviews, technical documentation review, and scenario analysis to produce practical laboratory-focused insights

The research methodology underpinning this executive summary combined a multi-layered approach to ensure balanced, reliable insights. Primary interviews with laboratory directors, pathologists, procurement managers, and R&D leads provided first-hand perspectives on operational priorities and pain points. Secondary sources included peer-reviewed literature on antibody technologies, reagent chemistries, and digital pathology innovations, as well as vendor technical documentation and regulatory guidance that contextualized validation and compliance considerations.

Analytical methods emphasized qualitative synthesis and triangulation, comparing stakeholder feedback with documented product specifications and implementation case studies. Special attention was paid to cross-referencing instrument compatibility matrices with reagent validation protocols to identify friction points in workflow integration. The research also incorporated scenario analysis to explore the implications of supply chain disruptions and tariff shifts on procurement strategies and capital investment decisions. Throughout, the focus remained practical: the goal was to translate technical advances into actionable guidance for laboratory and commercial decision-makers.

A synthesized concluding perspective emphasizing reproducibility, interoperability, and service-oriented strategies to translate immunohistochemistry advances into clinical impact

In summary, immunohistochemistry is evolving from a set of standalone techniques into an integrated tissue analytics ecosystem that combines advanced reagents, automated instruments, and digital analysis. Laboratories and suppliers that prioritize reproducibility, interoperability, and service support will create the conditions for sustainable adoption and clinical impact. The combined pressures of clinical demand for precision diagnostics, technological advances in multiplexing and imaging, and the realities of supply chain and regulatory environments require coordinated strategic responses from vendors and laboratory leaders alike.

By focusing on validated, interoperable solutions and investing in training and maintenance capabilities, organizations can protect assay integrity while capturing the benefits of increased throughput and analytical depth. The practical recommendations in this summary are intended to guide procurement teams, laboratory managers, and executive leaders as they navigate this period of transformation, translating technological potential into reliable, clinically meaningful outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immunohistochemistry Market, by Product Category

  • 8.1. Antibodies
    • 8.1.1. Primary Antibodies
      • 8.1.1.1. Monoclonal
      • 8.1.1.1.1. Mouse
      • 8.1.1.1.2. Rabbit
      • 8.1.1.2. Polyclonal
      • 8.1.1.3. Recombinant Monoclonal
      • 8.1.1.4. Recombinant Fragments
      • 8.1.1.4.1. scFv
      • 8.1.1.4.2. Fab
    • 8.1.2. Secondary Antibodies
      • 8.1.2.1. Enzyme-Conjugated
      • 8.1.2.2. Biotinylated
      • 8.1.2.3. Fluorophore-Conjugated
      • 8.1.2.4. Unconjugated
  • 8.2. Detection Systems
    • 8.2.1. Polymer
    • 8.2.2. Avidin-Biotin
    • 8.2.3. Tyramide Amplification
  • 8.3. Chromogens & Counterstains
    • 8.3.1. DAB
    • 8.3.2. AEC
    • 8.3.3. Fast Red
    • 8.3.4. Hematoxylin
  • 8.4. Ancillary Reagents
    • 8.4.1. Retrieval Buffers
    • 8.4.2. Blocking Reagents
    • 8.4.3. Wash Buffers
  • 8.5. Kits & Panels
    • 8.5.1. Single-Marker Kits
    • 8.5.2. Multiplex Panels

9. Immunohistochemistry Market, by Technology

  • 9.1. Chromogenic IHC
    • 9.1.1. HRP/DAB
    • 9.1.2. AP/Red
    • 9.1.3. Dual Enzyme
  • 9.2. Immunofluorescence
    • 9.2.1. Singleplex IF
    • 9.2.2. Multiplex IF
      • 9.2.2.1. 2-3 Plex
      • 9.2.2.2. 4-7 Plex
      • 9.2.2.3. 8+ Plex
  • 9.3. Signal Amplification
    • 9.3.1. Tyramide Signal Amplification
    • 9.3.2. Biotin-Based Amplification
  • 9.4. Metal-Conjugated IHC
    • 9.4.1. Mass Cytometry-Compatible
    • 9.4.2. MIBI-Compatible

10. Immunohistochemistry Market, by Specimen Type

  • 10.1. FFPE Tissue
    • 10.1.1. Resection
    • 10.1.2. Biopsy
  • 10.2. Frozen Tissue
    • 10.2.1. Cryosections
  • 10.3. Cytology Specimens
    • 10.3.1. Smears
    • 10.3.2. Liquid-Based Preparations
  • 10.4. Tissue Microarrays

11. Immunohistochemistry Market, by Application

  • 11.1. Clinical Diagnostics
    • 11.1.1. Oncology
      • 11.1.1.1. Solid Tumors
      • 11.1.1.2. Hematopathology
    • 11.1.2. Infectious Disease
    • 11.1.3. Transplant Immunopathology
    • 11.1.4. Neuropathology
    • 11.1.5. Cardiovascular Pathology
    • 11.1.6. Companion Diagnostics
  • 11.2. Research & Drug Discovery
    • 11.2.1. Basic Research
    • 11.2.2. Translational Research
    • 11.2.3. Target Validation
    • 11.2.4. Biomarker Discovery
    • 11.2.5. Toxicologic Pathology
  • 11.3. Veterinary Pathology
  • 11.4. Forensic Pathology
  • 11.5. Education & Training

12. Immunohistochemistry Market, by Indication

  • 12.1. Oncology
    • 12.1.1. Breast Cancer
    • 12.1.2. Lung Cancer
    • 12.1.3. Colorectal Cancer
    • 12.1.4. Prostate Cancer
    • 12.1.5. Melanoma
    • 12.1.6. Lymphoma
    • 12.1.7. Brain Tumors
  • 12.2. Infectious Diseases
    • 12.2.1. Viral
    • 12.2.2. Bacterial
    • 12.2.3. Fungal
  • 12.3. Autoimmune & Inflammatory
    • 12.3.1. Systemic Autoimmune
    • 12.3.2. Gastrointestinal Inflammatory
  • 12.4. Neurological Disorders
    • 12.4.1. Neurodegenerative
  • 12.5. Renal & Hepatic
    • 12.5.1. Renal Disease
    • 12.5.2. Hepatic Disease

13. Immunohistochemistry Market, by End User

  • 13.1. Hospital Laboratories
    • 13.1.1. Community Hospitals
    • 13.1.2. Academic Medical Centers
  • 13.2. Reference Laboratories
  • 13.3. Academic & Research Institutes
  • 13.4. Pharmaceutical & Biotechnology
    • 13.4.1. In-House Labs
    • 13.4.2. Outsourced Partners
  • 13.5. Contract Research Organizations
  • 13.6. Veterinary Pathology Laboratories

14. Immunohistochemistry Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Immunohistochemistry Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Immunohistochemistry Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Immunohistochemistry Market

18. China Immunohistochemistry Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Abcam plc
  • 19.7. Agilent Technologies, Inc.
  • 19.8. Becton, Dickinson and Company
  • 19.9. Bio-Rad Laboratories, Inc.
  • 19.10. Biogenex Laboratories, Inc.
  • 19.11. Cell Signaling Technology, Inc.
  • 19.12. Danaher Corporation
  • 19.13. Enzo Life Sciences, Inc.
  • 19.14. F. Hoffmann-La Roche Ltd
  • 19.15. Histo-Line Laboratories
  • 19.16. Leica Biosystems Nussloch GmbH
  • 19.17. Merck KGaA
  • 19.18. Miltenyi Biotec B.V. & Co. KG
  • 19.19. Novus Biologicals, LLC
  • 19.20. OriGene Technologies, Inc.
  • 19.21. PerkinElmer, Inc.
  • 19.22. R&D Systems, Inc.
  • 19.23. Santa Cruz Biotechnology, Inc.
  • 19.24. Sigma-Aldrich Co. LLC
  • 19.25. Takara Bio Inc.
  • 19.26. Thermo Fisher Scientific Inc.
  • 19.27. Vector Laboratories, Inc.
  • 19.28. Wako Pure Chemical Industries, Ltd.
  • 19.29. ZenBio, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMMUNOHISTOCHEMISTRY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SPECIMEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IMMUNOHISTOCHEMISTRY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IMMUNOHISTOCHEMISTRY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRIMARY ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRIMARY ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRIMARY ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRIMARY ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MONOCLONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MONOCLONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MONOCLONAL, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MOUSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MOUSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MOUSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RABBIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RABBIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RABBIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY POLYCLONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY POLYCLONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY POLYCLONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RECOMBINANT MONOCLONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RECOMBINANT MONOCLONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RECOMBINANT MONOCLONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RECOMBINANT FRAGMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RECOMBINANT FRAGMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RECOMBINANT FRAGMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RECOMBINANT FRAGMENTS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SCFV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SCFV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SCFV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SECONDARY ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SECONDARY ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SECONDARY ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SECONDARY ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ENZYME-CONJUGATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ENZYME-CONJUGATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ENZYME-CONJUGATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BIOTINYLATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BIOTINYLATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BIOTINYLATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FLUOROPHORE-CONJUGATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FLUOROPHORE-CONJUGATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FLUOROPHORE-CONJUGATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY UNCONJUGATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY UNCONJUGATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY UNCONJUGATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DETECTION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DETECTION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DETECTION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DETECTION SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AVIDIN-BIOTIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AVIDIN-BIOTIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AVIDIN-BIOTIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TYRAMIDE AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TYRAMIDE AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TYRAMIDE AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENS & COUNTERSTAINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENS & COUNTERSTAINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENS & COUNTERSTAINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENS & COUNTERSTAINS, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AEC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AEC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AEC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FAST RED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FAST RED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FAST RED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY HEMATOXYLIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY HEMATOXYLIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY HEMATOXYLIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANCILLARY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANCILLARY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANCILLARY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANCILLARY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RETRIEVAL BUFFERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RETRIEVAL BUFFERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RETRIEVAL BUFFERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BLOCKING REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BLOCKING REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BLOCKING REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY WASH BUFFERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY WASH BUFFERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY WASH BUFFERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY KITS & PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY KITS & PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY KITS & PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY KITS & PANELS, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SINGLE-MARKER KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SINGLE-MARKER KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SINGLE-MARKER KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MULTIPLEX PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MULTIPLEX PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MULTIPLEX PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENIC IHC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENIC IHC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENIC IHC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENIC IHC, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY HRP/DAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY HRP/DAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY HRP/DAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AP/RED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AP/RED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AP/RED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DUAL ENZYME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DUAL ENZYME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DUAL ENZYME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY IMMUNOFLUORESCENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY IMMUNOFLUORESCENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY IMMUNOFLUORESCENCE, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SINGLEPLEX IF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SINGLEPLEX IF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SINGLEPLEX IF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MULTIPLEX IF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MULTIPLEX IF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MULTIPLEX IF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MULTIPLEX IF, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY 2-3 PLEX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY 2-3 PLEX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY 2-3 PLEX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY 4-7 PLEX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY 4-7 PLEX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY 4-7 PLEX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY 8+ PLEX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY 8+ PLEX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY 8+ PLEX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SIGNAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SIGNAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SIGNAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SIGNAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TYRAMIDE SIGNAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TYRAMIDE SIGNAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TYRAMIDE SIGNAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BIOTIN-BASED AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BIOTIN-BASED AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BIOTIN-BASED AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY METAL-CONJUGATED IHC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY METAL-CONJUGATED IHC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY METAL-CONJUGATED IHC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY METAL-CONJUGATED IHC, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MASS CYTOMETRY-COMPATIBLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MASS CYTOMETRY-COMPATIBLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MASS CYTOMETRY-COMPATIBLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MIBI-COMPATIBLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MIBI-COMPATIBLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MIBI-COMPATIBLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FFPE TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FFPE TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FFPE TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FFPE TISSUE, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RESECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RESECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RESECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FROZEN TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FROZEN TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FROZEN TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FROZEN TISSUE, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CRYOSECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CRYOSECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CRYOSECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CYTOLOGY SPECIMENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CYTOLOGY SPECIMENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CYTOLOGY SPECIMENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CYTOLOGY SPECIMENS, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SMEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SMEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SMEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY LIQUID-BASED PREPARATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY LIQUID-BASED PREPARATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY LIQUID-BASED PREPARATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TISSUE MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TISSUE MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TISSUE MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY HEMATOPATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY HEMATOPATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY HEMATOPATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TRANSPLANT IMMUNOPATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TRANSPLANT IMMUNOPATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TRANSPLANT IMMUNOPATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY NEUROPATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY NEUROPATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY NEUROPATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CARDIOVASCULAR PATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CARDIOVASCULAR PATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CARDIOVASCULAR PATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RESEARCH & DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RESEARCH & DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RESEARCH & DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RESEARCH & DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TRANSLATIONAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TRANSLATIONAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TRANSLATIONAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TARGET VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TARGET VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TOXICOLOGIC PATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TOXICOLOGIC PATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TOXICOLOGIC PATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY VETERINARY PATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY VETERINARY PATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY VETERINARY PATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FORENSIC PATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FORENSIC PATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FORENSIC PATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EDUCATION & TRAINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EDUCATION & TRAINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY EDUCATION & TRAINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 266. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BRAIN TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BRAIN TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BRAIN TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 275. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 278. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 280. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 281. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 283. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FUNGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 286. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 288. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 289. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 290. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 291. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SYSTEMIC AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 292. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SYSTEMIC AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 293. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SYSTEMIC AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GASTROINTESTINAL INFLAMMATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 295. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GASTROINTESTINAL INFLAMMATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 296. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GASTROINTESTINAL INFLAMMATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 298. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 299. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 300. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 301. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 302. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY NEURODEGENERATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 303. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY NEURODEGENERATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 304. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RENAL & HEPATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 305. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RENAL & HEPATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 306. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RENAL & HEPATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 307. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RENAL & HEPATIC, 2018-2032 (USD MILLION)
  • TABLE 308. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RENAL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 309. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RENAL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 310. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RENAL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 311. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY HEPATIC DISEASE, BY REGION, 2018-2